Global Biopharmaceutical Contract Manufacturing Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Biopharmaceutical contract fabricating market is chiefly determined by increment in speculation of the pharma and biotechnological organizations to create and popularize the biotechnological items. What’s more, high income age of blockbuster organic medications, for example, humira, rituxan, lantus, avastin, herceptin and remicade are picking up footing from numerous biologics producers. Progressions in the biotechnology, for example, recombinant DNA advances and focused on tranquilize treatments are relied upon to reinforce the biopharmaceutical contract producing market over the gauge time frame. Besides, to take care of demand for organic items, organizations are outsourcing the biopharmaceutical assembling to different contract producing organizations. In any case, high cost related with fabricate and stringent administrative necessities are required to hamper the development of biopharmaceutical contract producing market.

A sample of this report is available upon request @

Biopharmaceutical contract manufacturing market segmented based on manufacturing process, type of services, molecule type and end user

Based on manufacturing process, biopharmaceutical contract manufacturing market is segmented into
• Mammalian Based
• Microbial Based
• Insect Based
• Plant Based
• Yeast Based
• Others

Based on type of service, biopharmaceutical contract manufacturing market is segmented into
• Formulation
• Fill and Finish services
• Cell Banking
• Analytical Services
• Process development
• Others

Based on molecule type, biopharmaceutical contract manufacturing market is segmented into
• Large Molecules
• Small Molecules

Based on end-user, biopharmaceutical contract manufacturing market is segmented into
• Biopharmaceutical Companies
• Pharmaceutical Companies
• Research Organizations
• Others

To view TOC of this report is available upon request @

Global biopharmaceutical contract manufacturing market is expected to grow at a significant rate during the forecast period. The market is highly competitive where the speed to market is imperative along with efficient process and low costs. Biopharmaceutical contract manufacturing services providers are increasing their service offerings such as formulation, production and analytical services apart from conventional services to provide complete support for biopharmaceutical companies. Cost considerations and quick services are expected continue to drive the outsourcing of biopharmaceutical contract manufacturing market. In May 2017, Lonza Group Ltd. acquired cell and gene contract manufacturer PharmaCell B.V., this acquisition broadens Lonza’s capabilities in Europe region. Companies expanding the manufacturing facilities to increase market share. For instance, In May 2017, Boehringer Ingelheim GmbH started a new manufacturing facility in China to increase their manufacturing capacity. Through this facility company’s manufacturing capacity will increase by one-third.

Geographically biopharmaceutical contract manufacturing market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America and Europe are expected to be leading in biopharmaceutical contract manufacturing owing to increased approvals of biosimilars and increase in biopharmaceutical research organization which are lack of manufacturing facilities. In Asia-Pacific region, emerging countries such as China and India expected to grow at a rapid rate owing to low cost of manufacturing. Development of biologics pipeline by domestic companies expected to drive the growth of biopharmaceutical contract manufacturing in China.

Need more information about this report @

Some of the players in biopharmaceutical contract manufacturing market are Lonza Group Ltd. (Switzerland), Boehringer Ingelheim GmbH (Germany), Charles River Laboratories, Inc. (U.S), Novartis AG (Switzerland) WuXi AppTec Group (China), Rentschler Biotechnologie GmbH (Germany), Fujifilm Holdings Corporation (Japan), Celonic AG (Switzerland), BIOMEVA GmbH (Germany), and ProBioGen AG (Germany) to name a few.

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,
152 – 160 City Road,
London EC1V 2NX


Toll Free (US): +1-866-598-1553

Leave a Reply

Designed by
Powered by
%d bloggers like this: